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Abstract.
Background: Neuropsychiatric symptoms in Huntington’s disease (HD) are often evident prior to clinical diagnosis. Apathy is
highly correlated with disease progression, while depression and irritability occur at different stages of the disease, both before
and after clinical onset. Little is understood about the neural bases of these neuropsychiatric symptoms and to what extent those
neural bases are analogous to neuropsychiatric disorders in the general population.
Objective:We used Diffusion Tensor Imaging (DTI) to investigate structural connectivity between brain regions and any putative
microstructural changes associated with depression, apathy and irritability in HD.
Methods: DTI data were collected from 39 premanifest and 45 early-HD participants in the Track-HD study and analysed using
whole-brain Tract-Based Spatial Statistics. We used regression analyses to identify white matter tracts whose structural integrity
(as measured by fractional anisotropy, FA) was correlated with HADS-depression, PBA-apathy or PBA-irritability scores in
gene-carriers and related to cumulative probability to onset (CPO).
Results: For those with the highest CPO, we found significant correlations between depression scores and reduced FA in the
splenium of the corpus callosum. In contrast, those with lowest CPO demonstrated significant correlations between irritability
scores and widespread FA reductions. There was no significant relationship between apathy and FA throughout the whole brain.
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Conclusions: We demonstrate that white matter changes associated with both depression and irritability in HD occur at different
stages of disease progression concomitant with their clinical presentation.
Keywords: Huntington’s disease, diffusion tensor imaging, depression, irritability, apathy
INTRODUCTION
Huntington’s disease (HD) is a neurodegenerative
disorder caused by an autosomal-dominant mutation
of the CAG repeat expansion in the huntingtin gene [1].
It primarily affects the medium spiny neurons within
the striatum, extending later throughout the cortex [2].
HD is monogenic and can readily be identified by
predictive testing. This combined with the full pene-
trance and ultimate certainty of disease onset facilitates
research into disease progression from its very early
stages.
The clinical phenotype of HD is characterised by
motor abnormalities [3], progressive cognitive deteri-
oration across a number of domains [4, 5], and a series
of more variable neuropsychiatric changes. Despite
depression, apathy and irritability all being highly
prevalent in HD [6, 7], most studies have focussed
principally or exclusively on motor and cognitive
decline and their association with disease progression.
However, apathy is clearly associated with disease pro-
gression, in terms of both severity [6, 8, 9] change
over time [4, 10], and cognitive and motor decline [10,
11]. In contrast, the relationship of depression and irri-
tability to disease progression is less well defined [7,
8]. Depressive symptoms often precede clinical onset
[12] peaking during early-HD stages and diminish-
ing as disease advances [10, 13]. The clinical features
of depression are similar to those in the general pop-
ulation [14], but they are seemingly independent of
cognitive decline [15], despite limited evidence that
higher levels of depression can impact cognitive func-
tion [16]. Irritability, which is highly correlated with
both impulsivity and aggression [9, 17] similarly corre-
lates with neither disease progression [7] nor cognitive
and motor decline [8, 15]. Rather there is some indica-
tion of increasing irritability in both premanifest [10,
13] and early disease stages [7, 13].
Neuroimaging has provided some insight into the
neural bases underlying depression, irritability and
apathy in the general population. Depression is asso-
ciated with a wide network of volumetric and white
matter structural abnormalities in regions including the
prefrontal and parietal cortices and the corpus callosum
[18], while irritability, due to the high correlation with
both impulsive and aggressive behaviours, has been
linked with dysfunction within ‘paralimbic’ regions,
such as the ventromedial prefrontal cortex [19]. Apathy
is less well characterised, but has been putatively asso-
ciated with abnormal function of the frontal lobe [20].
There is, however, very little information regarding the
underlying neural bases of the same neuropsychiatric
disorders within HD. One study using structural imag-
ing has demonstrated a relationship between reduced
anterior cingulate volume in gene-carriers and depres-
sion scores [21] but other studies have shown no such
association [22]. There is also evidence of reduced
structural connectivity in frontal regions in a depressed
HD group [23] and decreased prefrontal activity related
to increased depression scores and reduced cogni-
tive performance in premanifest-HD [16]. Likewise,
increased irritability, has been associated with reduced
amygdala activity and connectivity between brain
regions involved in emotion processing and regula-
tion [24], while apathy levels correlate with reduced
structural connectivity in the rectus gyrus [25]. How-
ever, despite these findings, neurobiological evidence
for neuropsychiatric symptoms in HD is both mixed
and limited.
Structural MRI shows that white matter atrophy is
a good marker of disease progression in early-HD and
acts as an independent predictor of disease onset [4,
26, 27]. Given that white matter structure can influence
local diffusion, changes in structure may manifest as
changes in local diffusion of water. Diffusion Tensor
Imaging (DTI) can be used to examine white matter
microstructure. DTI measures orientation distribution
of diffusion, with a principal outcome measure of frac-
tional anisotropy (FA) that describes the directionality
of diffusion. In HD, a pattern of congruent reductions
in FA and increases in mean diffusivity (overall dif-
fusion), acts as a marker of disease progression and
predictor of onset in those very close to diagnosis
[28–30]. Only two studies have specifically examined
diffusion anomalies associated with neuropsychiatric
disturbance in HD. The first demonstrated associa-
tions between apathy levels in HD patients and reduced
white matter FA in the rectus gyrus [25], while the sec-
ond compared HD diagnosed patients with and without
depression [23] and demonstrated reduced FA in infe-
rior frontal regions, the anterior cingulate, the insula
and the cerebellum. However, the low median thresh-
old used for identifying depression in this study may
have resulted in a heterogeneous ‘depressed’ group.
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Here, we investigated the relationship between the
three most prevalent neuropsychiatric symptoms in HD
(depression, apathy and irritability/aggression) and
white matter microstructure in a large group of pre-
manifest and clinically-diagnosed HD gene-carriers
recruited from the final visit of the multi-site Track-HD
study [4]. Given the inconsistent evidence regarding
the underlying neural basis for each symptom in HD,
we adopted a whole-brain DTI-analysis technique,
Tract-Based Spatial Statistics (TBSS) [31]. Several
studies have used TBSS in HD populations and found
widespread changes in both premanifest and diagnosed
gene-carriers. Since the division between premanifest
and early HD is somewhat arbitrarily defined by motor
onset, gene-carrier participants were analysed as a con-
tinuous group. In addition to the possible association
between FA and neuropsychiatric symptoms, we also
examined the relationship between neuropsychiatric
measures and FA as a function of cumulative proba-
bility to onset (CPO) [32]. We specifically predicted
that reduced FA in relation to CPO and neuropsychi-
atric measures would be evident for depression, apathy
and irritability/aggression corresponding to the clinical
presentation of these symptoms, with most abnormali-
ties related to apathy and irritability found in the frontal
regions. However, we also examined the whole brain
to identify any associations between diffusivity and
neuropsychiatric symptoms in other brain areas.
MATERIALS AND METHODS
Participant information
Forty-five HD gene carriers and thirty-nine
premanifest-HD subjects who had undergone a DTI
scan were recruited from the final time point of the
multi-site Track-HD study [4] (see Supplementary
Information). For the apathy analyses, one premani-
fest and two early-HD participants were excluded due
to missing neuropsychiatric data. Inclusion criteria and
participant recruitment have been described previously
[33]. We used cumulative probability to onset (CPO),
which acts as a stronger predictor of many HD phenom-
ena both before and after the point of diagnosis [32].
The study was approved by the local ethics commit-
tees and all participants gave written informed consent
according to the Declaration of Helsinki.
Neuropsychiatric measures
As part of the Track-HD study an annual interview
to survey neuropsychiatric signs and symptoms asso-
ciated with HD was carried out by a trained rater. The
following scales were used:
Hospital Anxiety and Depression Scale (HADS)
The HADS is a 14-item self-report tool, designed to
obtain a brief rating of depression and anxiety symp-
toms that reflects primarily mood rather than cognitive
and somatic symptoms. Each item is scored on a 0–3
scale. Seven items each relate to anxiety and depression
producing separate anxiety and depression sub-scores,
each with a maximum of 21. The HADS provides a
more quantitative measure of depression than the Prob-
lem Behaviours Assessment depression scale and is
less susceptible to confounds from somatic symptoms
in HD than the Beck Depression Inventory [34].
Problem Behaviours Assessment (PBA)
The short version of the PBA-s [35] is a concise
version of the Problem Behaviours Assessment for
HD (PBA-HD) [17]. It is a semi-structured interview
designedtoassesselevenpsychiatricsymptomsthought
to be potentially most relevant to HD: low mood, sui-
cidal ideation, anxiety, irritability, angry or aggressive
behaviour, apathy, perseverative thinking or behaviour,
obsessive compulsive behaviour, paranoid/delusional
thinking or behaviour, hallucinations and behaviour
suggesting disorientation. Individual items are scored
on a five-point scale for severity and frequency respec-
tively (previous four weeks) and multiplied for an
overall score. Raters were trained, and all interviews
recorded with a random subsample reviewed by an
experienced rater. Factor analysis of PBA-HD data [8,
17] identified three main factors: apathy, irritability/
aggression, and affective symptoms. For irritability, an
integrated irritabilityandaggressionscorewasuseddue
to the high level of correlation in HD [9, 17].
Medication
Neuroleptic and antidepressant drugs are widely
used to treat disturbances of mood and motor function-
ing in HD. As a naturalistic study of premanifest gene
carriers and patients during early stage disease, partic-
ipants in the Track-HD cohort were commonly using
these medications, which could potentially reduce
depression or irritability scores and/or worsen apathy
scores. Medication use (SSRIs, SNRIs, neuroleptics,
tricyclics, bupropion, benzodiazepines, anti-epileptics
and tetrabenazine) was recorded in detail and used to
create a binary code dependent on presence/absence of
medication at the visit that may affect mood, irritability,
or apathy scores.
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Behavioural measures
All participants underwent a broad range of cogni-
tive and quantitative motor tests known to be sensitive
in HD. For full details see [33, 36]. In the current
study, we used three tasks as markers of cognitive and
motor performance. The Symbol Digit Modalities Test
(SDMT) is a test of visuomotor integration, measur-
ing visual attention and motor speed. The participant
was given 90 seconds to match symbols and digits as
quickly as possible, following a key located at the top
of the page, and the total number of correct responses is
recorded. Spot the Change is a visual working memory
task in which the participant was required to view an
array of five coloured squares that were presented for
250 ms. After 1000 ms a similar array was presented
with one of the squares encircled. Participants decided
whether the square within the circle is the same as in
the original array or has changed in colour. The out-
come is Cowan’s K formula for estimating the number
of items encoded at each set size [37] which assesses
individual differences in the flexibility of the scope
of attention. During Speeded Tapping the participant
placed their non-dominant hand palm down on a sup-
port surface located on the table in front of a force
transducer such that they could comfortably tap on the
surface with their index finger. A cuing tone was pre-
sented at 1·8 Hz and subjects were instructed to tap
at the same rate as the cue and to continue tapping
at this rate when the cuing tone stopped. Five trials
were performed. The participant continued to tap for
10 seconds after the cuing tone ceased. Speeded Tap-
ping Tap Duration Variability, was calculated during
this period from the tap deviation from the pre-defined
1·8 Hz frequency [38].
Imaging data acquisition
Structural imaging data collection has been
described previously [33]. DTI data were acquired
using 3T MRI Siemens Trio (London and Paris)
and Philips (Leiden) scanners (see Supplemen-
tary information for Quality Control information).
Diffusion-weighted images with 42 unique gradi-
ent directions (b = 1000 sec/mm2) were collected with
either seven images (Siemens) with no diffusion
weighting or one image with no diffusion weighting
(Phillips). For scans collected in London, dimensions
were 128 pixels × 96 pixels × 65 slices per volume,
with TE = 84 ms and TR = 7600 ms; for Paris, dimen-
sions were 128 pixels × 128 pixels × 75 slices per
volume, with TE = 88 ms and TR = 13100 ms and for
Leiden, dimensions were 112 pixels × 112 pixels × 55
slices per volume, with TE = 56 ms and TR = 8078 ms.
Voxel size for Siemens scans was 2 × 2 × 2 mm3 and
for Phillips 1.96 × 1.96 × 2mm3.
Data analyses
Demographic, clinical and neuropsychiatric data
were analysed using independent t-tests and Chi-
Squared tests in SPSS v.19.0. Prior to analysis, each
DTI dataset was manually scanned for artefacts, signal
drop-out, and motion; quality assurance was performed
after each pre-processing step. The diffusion data were
pre-processed using standard pipelines within the FSL
data analysis package [39]. Data were first corrected for
distortions caused by eddy currents, and motion using
FSL’s eddy correct and vector gradient information was
updated accordingly. The no-gradient (b = 0) image
was then skull-stripped using the Brain Extraction Tool
(BET), manually examined, corrected if required, and
diffusion-tensor fit to the corrected data. For the TBSS
analysis [31], all diffusion tensor data were then regis-
tered to a customized diffusion tensor template using
DTI-TK [40] to achieve optimal alignment of white
matter. The customized template used diffusion tensor
maps from 18 participants (three premanifest and three
manifest from each site) and was created using a boot-
strapping process and iterative spatial normalization.
The tensor volume for each subject was then registered
to the final template using linear (rigid and affine) and
nonlinear registration and resliced into high-resolution
(1mm3); the mean FA skeleton was generated. Using
TBSS analysis, the mean FA image was thresholded
to include voxels with mean FA of 0.2 and each par-
ticipant’s FA data projected onto the skeleton. Using
the FSL GLM Randomise tool, cross-subject statis-
tics were performed on all voxels within the FA
skeleton mask using non-parametric permutation tests
(n = 5000) [41]. The premanifest and manifest partic-
ipants were modelled together to investigate the main
effects of each neuropsychiatric measure and CPO
respectively on FA. Our primary interest, however, was
the interaction between each neuropsychiatric mea-
sure and CPO on levels of FA. Confounder variables
included age, sex, site and intracranial volume (ICV),
which was generated as described previously [42]. All
analyses were repeated to include medication use (for
depression using SSRI/SNRI only; for apathy and irri-
tability/aggression using all medication as described
in the methods). Threshold-Free Cluster Enhancement
(TFCE) was used for cluster identification and all
results were corrected for multiple comparisons using
S. Gregory et al. / Neuropsychiatry and Microstructure in HD 243
an FWE-threshold of p < 0.05. To further understand
any significant interactions, FA values were extracted
for each participant using a mask containing all sig-
nificant voxels thresholded at the corrected P < 0.05.
Conditioning plots were generated purely for visual-
ization purposes of significant statistical relationships.
A conditioning plot consists of a series of scatterplots
depicting the relationship between FA and a neuropsy-
chiatric variable, each a function of CPO. Subsamples
of the data are selected based on overlapping intervals
of CPO and a linear regression curve fit for each scat-
terplot. Finally, using Spearman’s Rho the extracted
FA values were correlated with the three measures of
cognitive and motor performance using SPSS v.22.
RESULTS
Demographic and clinical measures
Table 1 shows relevant descriptive and inferential
statistics for the premanifest-HD and early-HD groups.
The early-HD participants were significantly older
than the premanifest participants. This was expected
given that HD is a progressive disease. There were no
statistically significant differences in gender, educa-
tion, or in the delineation of participants across site. For
the gene-carrier groups, as expected, there were signifi-
cant differences in CPO, but no significant difference in
CAG length. Finally, there was a significant difference
for irritability and apathy and a borderline significant
difference for depression (See Supplementary Data for
site-specific analyses).
Relationship between CPO and fractional
anisotropy
We found widespread significant (corrected
P < 0.05) negative correlations between CPO and FA
across the whole brain in a series of white matter
tracts, principally the corpus callosum (body, genu and
splenium), bilateral anterior, superior and posterior
corona radiata, left posterior thalamic radiation, and
right superior longitudinal fasciculus. There were
additional significant negative correlations between
CPO and FA in the right internal capsule, the inferior
longitudinal and inferior fronto-occipital fasciculi
(see Supplementary Data: Table 1 and Fig. 1).
Relationship between neuropsychiatric measures
and fractional anisotropy
HADS depression
There were no significant correlations between
HADS depression scores and FA across the whole
brain (correctedP > 0.05). There was a significant asso-
ciation between FA and the HADS depression scores as
CPO varied that was localized to the body and the sple-
nium of the corpus callosum (corrected P = 0.014 for
right, P = 0.009 for left) (Table 2; Fig. 1a). For higher
CPO, FA decreased as HADS depression increased;
this negative relationship diminished for lower CPO
(Fig. 1b). These results remained significant when
controlling for the effects of SSRI/SNRI medication
(corrected P < 0.05) (See Supplementary Data for site-
specific analyses).
Table 2
Tracts in which reduced FA was significantly correlated with
increased levels of HADS depression for those with high CPO;
FWE–corrected threshold of p < 0.05
Maximum Intensity Voxels p-value White
Voxel Matter tracts
x y z
105 80 86 444 0.014 Left Splenium
Left Callosal Body
121 83 91 386 0.009 Right Splenium
Right Callosal Body
Table 1
Comparisons of demographic, clinical and behavioral characteristics of premanifest and early-HD gene-carrier participants; FET = Fisher’s
Exact Test
Premanifest-HD Early-HD Statistic P-Value
Age (mean, sd) 42.5 (7.9) 49.4 (10.1) t(81.3) = 3.55 <0.001
Sex (female, %) 20 (51%) 29 (64%) X(1) = 1.489 0.222
Education (median) 4 4 FET = 3.947 1
Site (no.) London 16 18 X(2) = 0.013 0.994
Paris 16 19
Leiden 7 8
CAG Repeat (mean, range) 42.85 (39–48) 43.33 (39–49) t(82) = 0.667 0.507
CPO (mean, sd) 0.229 (0.15) 0.539 (0.23) t(82) = 7.137 <0.001
HADS depression (mean, sd) 2.97 (3.58) 4.71 (4.39) t(82) = 1.97 0.053
PBA Irritability and Aggression (mean, sd) 2.23 (3) 4.38 (5.2) t(72) = 2.356 0.021
PBA Apathy (mean, sd) 2.45 (4.08) 5.53 (5.66) t(76.1) = 2.84 0.006
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Fig. 1. Tracts in which reduced FA was correlated with increased levels of depression in those with high CPO; FWE -corrected threshold
of P < 0.05. a) Results (red-yellow) are projected on a white matter skeleton (green), overlaid on a customized mean FA image. b) FA as a
function of HADS depression (lower scatterplots), conditional on CPO (upper panel). The upper panel depicts the overlapping ranges of CPO
that determine the subsample of each scatterplot. A linear regression line was fit for each scatterplot to aid interpretation.
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Fig. 2. Tracts in which reduced FA was correlated with increased levels of irritability/aggression in those with low CPO; FWE-corrected
threshold of P < 0.05. a) Results (red-yellow) are projected on a white matter skeleton (green), overlaid on a customized mean FA image. FA as
a function of PBA irritability/aggression (lower scatterplot), conditional on CPO (upper panel). The upper panel depicts the overlapping ranges
of CPO that determine the subsample of each scatterplot. A linear regression line was fit for each scatterplot to aid interpretation.
PBA irritability/aggression
There were significant negative correlations between
irritability/aggression scores and FA across the whole
brain; these were located in the left hemisphere only
(corrected P < 0.05). Tracts that demonstrated such a
correlation were the body of the corpus callosum and
fornix, the retrolenticular and posterior limb of the
internal capsule, the external capsule, the posterior and
superiorcorona radiate, theposterior thalamic radiation
and the inferior fronto-occipital, inferior longitudinal
and superior longitudinal fasciculi. There were no
positive correlations between FA and irritability/
aggression scores across the whole brain (corrected
P < 0.05). There was a significant association between
FA and the irritability/aggression scores as CPO
varied (corrected P < 0.05). Again this was widespread
across the brain in the same white matter regions in
which we saw negative correlations between irritabil-
ity/aggressionandFA(Table3;Fig.2a).For lowerCPO,
FA decreased as PBA irritability/aggression scores
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Table 3
Tracts in which reduced FA was correlated with increased levels of irritability/aggression in those with
low CPO; FWE-corrected threshold of p < 0.05
Maximum Intensity Voxel Voxels p-value White Matter tracts
x y z
76 78 69 1235 0.019 Left Retrolenticular Internal Capsule
Left Posterior Corona Radiata
Left Posterior Thalamic Radiation
Left External Capsule
Left Superior Longitudinal Fasc.
Left Inferior Longitudinal Fasc.
Left Inferior Fronto-Occipital Fasc.
Left Fornix
90 74 95 706 0.03 Left Callosal Body
Left Posterior Corona Radiata
Left Superior Corona Radiata
Left Superior Longitudinal Fasc.
increased; this negative relationship was reversed
as CPO increased (Fig. 2b). These results remained
significant when controlling for the effects of all medi-
cation (corrected P < 0.05). We predicted that elevated
irritability/aggression would be associated with frontal
white matter anomalies. Thus, we examined white
matter changes in the frontal lobe at an uncorrected
threshold and identified similar negative correlations
in the left uncinate fasciculus (uncorrected P < 0.001)
(See Supplementary Data for site-specific analyses).
PBA apathy
There were no significant overall correlations
between PBA apathy scores and FA, and no significant
interaction of CPO that affected this relationship
(corrected P < 0.05). This remained the case when
controlling for the effects of all medication. We
predicted that elevated apathy would be associated
with frontal white matter anomalies. Therefore, we
further investigated this area at an uncorrected level of
P < 0.001. However, even at this more liberal threshold
no significant associations were identified for the sim-
ple relationship between apathy and FA or as a function
of CPO (See Supplementary Data for site-specific
analyses).
Correlations between behaviour and FA
There were positive correlations between FA val-
ues for the Depression-CPO interaction and SDMT
(r = 0.453, p = 0.001) and Spot the Change (r = 0.310,
p = 0.004). This indicates that in those HD gene-
carriers with higher levels of depression and who
are closer to onset (Fig. 1b) cognitive performance
declined as FA decreases. There was also a signif-
icant negative relationship between speeded tapping
duration and FA values for the Depression-CPO inter-
action (r = –0.376, p = 0.001), which likewise shows
that motor performances worsened as FA decreased
in those with higher levels of depression. There were
congruent positive correlations between FA values
for the Irritability/Aggression-CPO interaction and
SDMT (r = 0.409, p = 0.001) and Spot the Change
(r = 0.285, p = 0.009). Similarly to depression, this
indicates that in those HD gene-carriers with higher
levels of irritability/aggression and who are further
from onset (Fig. 2b) cognitive performance declined
as white matter abnormalities increase. However, there
was no significant relationship between speeded tap-
ping and FA values for the Irritability/Aggression-CPO
interaction (r = –0.163, p = 0.140).
DISCUSSION
This is the first study to use multi-site diffusion imag-
ing data to investigate relationships between neuropsy-
chiatric symptoms and white matter microstructural
change in a large cohort of premanifest and clinically-
diagnosedHDgene-carriers.Wedemonstratedthatboth
depression and irritability scores were associated with
widespread changes in FA, conditional on CPO. FA
decreased as both depression symptoms increased in
those with high CPO, FA also decreased as irritability/
aggression symptoms increased, but only in those with
low CPO. We found no relationship between apathy and
diffusivity.
Depressive symptoms are highly prevalent in HD,
occurring in 40–50% of gene carriers [7], but their
timecourse in terms of disease progression is less well
understood. Symptoms seem to emerge most signif-
icantly in the premanifest and early diagnosis stages,
but do not change significantly over time [7, 10, 13]. In
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the current study, the highest level of disease severity is
that of Stage 2 [43], equivalent to the mild to moderate
stages of clinically-diagnosed HD. We have shown that
in those with high CPO, deterioration of white matter
microstructure within the corpus callosum is associ-
ated with increased levels of depressive symptoms.
This supports existing evidence that those with early
stage disease are most impacted by depression and fur-
ther suggests that this may be underscored by localized
changes in white matter microstructure. Although in
the current study we have used CPO, a measure of
predicted disease severity, rather than total functional
capacity (TFC), a measure of actual disease severity,
the strong relationship between these two measures [4]
validates its use here. Similarly, there is limited evi-
dence to suggest that irritability/aggression is robustly
related to disease progression [7, 8, 10], but there
are indications that it is observed prior to other neu-
ropsychiatric symptoms in premanifest gene-carriers
[8, 10, 13]. We have shown that in those with low CPO
(nominally furthest from clinical onset) widespread
changes in white matter microstructure are associated
with increased levels of irritability/aggression. This
relationship diminishes in those with the highest CPO.
This again supports existing clinical evidence that high
levels of irritability/aggression are evident in those fur-
thest from disease onset and that these changes are
underscored by widespread decreases in white matter
microstructural organization.
Depression-related decreases in FA were located
mainly within the posterior corpus callosum. This
region facilitates interhemispheric communication and
given its connectivity to all four lobes is involved in
the transference of motor, sensory and cognitive infor-
mation. Changes in white matter structure throughout
the brain including that of the corpus callosum are
common in depression in the general population [44]
and it is a structure that degenerates throughout the
time course of HD [45]. Interestingly, the white matter
changes we found were isolated to the more poste-
rior body and splenium of the callosum which also
show abnormalities in depressive disorders [46, 47]
and are consistent with reported microstructural degen-
eration in HD [45]. This is perhaps unsurprising given
the evidence for early wholesale cortical white mat-
ter degeneration in the posterior cortex, which later
extends more widely to involve midline and frontal
regions [48]. Grey matter atrophy may also begin in the
posterior, occipital regions, albeit at a much slower rate
than in white matter [48]. Thus, despite indications that
depressive symptomatology does not differ consider-
ably from those of depression per se [14], changes at
the microstructural level suggest that depression may
be more associated with the white matter changes char-
acteristic of HD progression. Furthermore, a decline in
both motor and cognitive performance was associated
with decreased FA values in those with higher levels of
depression suggesting that the depression may be asso-
ciated more globally with disease progression. This
speculation should be clarified in future work explicitly
comparing HD participants with depressive symptoms
with matched depressed non-HD control participants.
Interestingly, in a previous study, increased Stroop-
interference related activity in the ventromedial pre-
frontal cortex was associated with an increase in
depression scores in premanifest HD [49]. It was sug-
gested that this may reflect changes in network activity
in the anterior regions of the brain. These functional
connectivity changes are compatible with our findings
in which structural degeneration associated with higher
levels of depression occurs in more posterior white
matter tracts. Given that the previous study investi-
gated only premanifest HD participants, however, we
cannot comment on the extent to which observed func-
tional connectivity changes are comparable in the early
disease stage.
Unlike depression, irritability/aggression is under-
scored by more specific morphological changes,
which, given the close association with impulsive
behaviour, occur in ventromedial prefrontal, medial
temporal regions [50]. In the current study, there was
some evidence of microstructural change in frontal
connections at an uncorrected threshold, but it was
changes in posterior tracts relating to irritability/
aggression levels that were most prevalent and
widespread. This suggests that elevated levels of irri-
tability and aggression that arise in HD may be due not
to impulsive traits but instead to cognitive overload.
Situations in which an individual becomes cognitively
overstretched can lead to increased irritability. This
might be particularly true for those with early symp-
tom onset, such that as executive function begins to
deteriorate, irritability levels rise. This is supported by
robust evidence of irritability in those up to 10 years
prior to onset [13]. To test this further, we investi-
gated the relationship between FA and three cognitive
and motor performance markers that are robustly sen-
sitive to HD progression [4]. Both SDMT and Spot
the Change performance were positively associated
with FA values for the irritability/aggression interac-
tion indicating that those with high irritability, who
were furthest from onset, showed decreased global FA
and a corresponding decline in cognitive performance.
Furthermore, this relationship was not significant for
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speeded tapping performance and thus specific to cog-
nitive behaviour. We have shown that not only does
irritability occur in those with lower CPO but that this
is underscored by changes in white matter microstruc-
ture characteristic of HD progression. This is further
reinforced by the fact that all abnormalities associated
with irritability/aggression were located within tracts
in the left hemisphere. The left hemisphere appears
to degenerate first, with evidence of right-hemisphere
compensation behaviour during task-based fMRI and
in resting state networks of global cognition [51]. Left
hemisphere degeneration may also motivate neuropsy-
chiatric symptomatology.
Apathy is the neuropsychiatric symptom most
robustly associated with disease progression [4, 7–10]
and cognitive and motor dysfunction [10, 11, 15]. In the
current study, however, there was no discernible rela-
tionship between apathy and white matter change; even
when controlling for the effects of medication. A pre-
vious study using data form the Track-HD study shows
a negative relationship between apathy and the rectus
gyrus using region of interest analyses [25]. However,
that previous study used only single site data from the
first timepoint of the study. Grey matter degeneration
tends to be preceded by that of white matter; given the
robust association of apathy and disease progression, it
is possible that apathy in HD is related not to white mat-
ter microstructural changes but instead to that of grey
matter. It is important to remember that there may be an
inherent bias within the current sample given that those
with the lowest levels of apathy may be most likely to
participate in such a study; those with the most pro-
found apathy and possibly most profound changes in
brain structure may be absent.
It is important to note that volumetric loss is proba-
bly the most established measure of change within the
brain during the premanifest HD stage. In the current
study, we used DTI data from the 36-month time-
point of the Track-HD study and information regarding
structural change within this cohort has already been
published in previous Track-HD articles [4, 33, 48, 52].
In the current study, we chose a non-morphological
measure of disease progression, as changes in struc-
tural volume, either for the striatum or whole brain
reflect more directly the neurodegenerative pathology
associated with HD progression. It is, therefore, possi-
ble that an association between brain volume, white
matter microstructural change and neuropsychiatric
scores would be confounded by this (see Supplemen-
tary Data for further information).
Therearesomelimitationsof thecurrent study.Using
data from multiple sites can introduce possible site
effects. However, strict quality control procedures were
conductedateachsitetoensureconsistencyacrossscans
and all data were visually inspected for potential site-
specific artefacts. Furthermore, site was also included
withinthestatisticalmodel.Wealsoperformedanalyses
on data from each site independently for both neu-
ropsychiatricscoresandFAchange(seeSupplementary
Data). The large numbers within the Track-HD cohort
and the high levels of quality assurance and standard-
ization of protocols and pipelines, in addition to the
enhanced registration suggest that the findings within
thisstudyarerobust.Neuropsychiatricsymptomscanbe
difficult to quantify. However, through training, quality
control and high inter-rater reliability it has been shown
that scores can be reliably measured [35].
This is the first study to use multi-site DTI data
to investigate the relationship between white mat-
ter microstructure and neuropsychiatric disturbance
in both premanifest and early-HD participants. We
have demonstrated congruent increases in depression
symptoms and decreases in FA in those with high
CPO. Similarly, we have also shown that increases
in irritability are associated with higher levels of FA
in those with low CPO and therefore, furthest from
onset. These findings are compatible with the clinical
timecourse of neuropsychiatric symptoms and indicate
that white matter changes may impact their onset in
different ways. These findings are highly relevant in
extending our understanding of changes in white mat-
ter microstructure and its potential impact on the onset
and duration of neuropsychiatric symptoms in HD.
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